General Information of Drug (ID: DML53GP)

Drug Name
Tendamistat Drug Info
Synonyms Tendamistat (12-26); 135307-06-1; Glycine, L-valyl-L-threonyl-L-leucyl-L-tyrosyl-L-glutaminyl-L-seryl-L-tryptophyl-L-arginyl-L-tyrosyl-L-seryl-L-glutaminyl-L-alanyl-L-alpha-aspartyl-L-asparaginyl-
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
16131388
CAS Number
CAS 135307-06-1
TTD Drug ID
DML53GP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Alpha-glucosidase (GLA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cipaglucosidase alfa DMAPDH2 Glycogen storage disease type II 5C51.3 Approved in EU [2]
Cipaglucosidase alfa DMAPDH2 Glycogen storage disease type II 5C51.3 Approved in EU [3]
Deoxynojirimycin DM2ATZB Pompe disease 5C51.3 Phase 3 [4]
Anamorelin DM6HXTS Carbohydrate metabolism disorder 5C51.Z Phase 3 [5]
Maltose DMH0ROP N. A. N. A. Phase 1/2 [6]
AAV2/8-LSPhGAA DMIX5HF Pompe disease 5C51.3 Phase 1 [7]
Nicotinamide-Adenine-Dinucleotide DM9LRKB N. A. N. A. Investigative [8]
Beta-D-Glucose DM5IHYP Discovery agent N.A. Investigative [8]
Double Oxidized Cysteine DM6TU84 Discovery agent N.A. Investigative [8]
POP-1 DMVTKCX Solid tumour/cancer 2A00-2F9Z Investigative [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Alpha-glucosidase (GLA) TTHCF4J LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN Inhibitor [1]

References

1 Influence of Specific Signal Peptide Mutations on the Expression and Secretion of the alpha -Amylase Inhibitor Tendamistat in Streptomyces lividans. J Biol Chem. 1996 Jun 21;271(25):15244-52.
2 Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
3 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
4 Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
5 Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
6 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
7 ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.